Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 3110  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
 :: Next article
 :: Previous article 
 :: Table of Contents
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::Related articles
 ::  Article in PDF (147 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  Abstract
 ::  Materials and Me...
 ::  Results
 ::  Discussion
 ::  Conclusion
 ::  References
 ::  Article Figures
 ::  Article Tables

 Article Access Statistics
    Viewed8057    
    Printed131    
    Emailed5    
    PDF Downloaded372    
    Comments [Add]    
    Cited by others 5    

Recommend this journal


 


 
ORIGINAL ARTICLE
Year : 2008  |  Volume : 54  |  Issue : 4  |  Page : 252-258

Gender-based treatment outcomes in diabetic hypertension


1 Primary Care, Ministry of Health Manama, Manama, Bahrain
2 Department of Pharmacology and Therapeutics, Arabian Gulf University, Manama, Bahrain

Date of Submission24-Jun-2007
Date of Decision03-Apr-2008
Date of Acceptance11-Jun-2008

Correspondence Address:
KAJ Al Khaja
Department of Pharmacology and Therapeutics, Arabian Gulf University, Manama
Bahrain
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0022-3859.41433

Rights and Permissions


 :: Abstract 

Background: In developing countries, gender-based treatment disparities in cardiovascular preventive therapy have received little attention. Aims: To evaluate the gender-based differences in cardiovascular disease risk profile, drug prescribing pattern, and blood pressure (BP) and glycemic control rates in diabetic hypertensives treated at primary care setting in Bahrain. Settings and Design: A retrospective study at primary care setting. Materials and Methods: An audit of the medical records of 392 diabetic hypertensives (127 men, 265 women). Results: BP and glycemic targets were achieved in <10% and <13% of diabetic hypertensives, respectively. Angiotensin converting enzyme inhibitors monotherapy was more often prescribed in males. Apart from this, no significant differences in prescribing pattern were observed between male and female diabetic hypertensives treated with either antihypertensive mono or multidrug therapies. With the exception of insulin which was more often prescribed to females, a similar prescribing pattern and rank order of antidiabetics, either as monotherapy or combinations, was observed in both genders. The majority of diabetic hypertensives were at high cardiovascular risk. The body mass index and total cholesterol level were greater in females. Prescribing lipid-lowering drugs and aspirin were suboptimal; aspirin was more often prescribed to males. There was no gender-based difference with regard to the use of lipid-lowering drugs. Conclusions: BP and glycemic controls were suboptimal in both male and female diabetic hypertensives treated by primary care physicians. Cardiovascular disease preventive strategies have received little attention regardless of gender or other risk factors. Gender-based treatment inequities also need to be addressed.


Keywords: Blood pressure control, cardiovascular preventive therapy, cardiovascular risk factors, gender-based treatment disparities, glycemic control, primary care in developing countries


How to cite this article:
Damanhori A, Al Khaja K, Sequeira R P. Gender-based treatment outcomes in diabetic hypertension. J Postgrad Med 2008;54:252-8

How to cite this URL:
Damanhori A, Al Khaja K, Sequeira R P. Gender-based treatment outcomes in diabetic hypertension. J Postgrad Med [serial online] 2008 [cited 2019 Aug 24];54:252-8. Available from: http://www.jpgmonline.com/text.asp?2008/54/4/252/41433


The classic cardiovascular risk factors are consistent and common but are largely undertreated and uncontrolled in many regions of the world [1],[2] and result in high rate of cardiovascular events. [3] Hypertension is extremely common in patients with type 2 diabetes [4] and the co-existence of hypertension and diabetes increases the risk of macrovascular and microvascular complications. [5] These complications are significantly reduced by optimal control of blood pressure (BP). [5],[6],[7] The primary goal of antihypertensive treatment in patients with diabetes is to lower BP, whenever possible, below 130/85 mm Hg. [8] Effective and complementary combinations of two or more antihypertensives are often needed to achieve the target BP goal in diabetic patients. [8],[9],[10],[11],[12]

Low-dose aspirin is considered as a primary prevention strategy in high-risk diabetics to reduce adverse clinical outcomes, [13] especially of major cardiovascular events. [6],[14] Lipid-lowering therapy results in greater reduction in the rate of coronary events in diabetic subjects than in nondiabetic ones. [15],[16] Patients with type 2 diabetes without prior myocardial infarction (MI) have a risk of infarction similar to that among nondiabetic patients with a prior MI suggesting that all persons with diabetes should be treated with lipid-lowering agents as if they had prior coronary heart diseases. [17]

Gender considerations are important in pathophysiology and treatment of hypertension, and gender-related adverse effects of antihypertensives may limit the choice of drug therapy. Hypertension during pregnancy, use of oral contraceptives, menopause and estrogen replacement therapy may influence the BP regulation in ways that have therapeutic implications for some women. [18]

Recent studies from developed countries have addressed gender differences in control of hypertension, diabetes, and other cardiovascular risk factors in diabetic hypertensive patients. [19],[20],[21],[22] In this primary-care based study from a developing country, Bahrain, the gender-based differences in cardiovascular risk factor profile (including risk prevention treatment), drug prescribing pattern, and BP and glycemic control rates in patients with hypertension and type 2 diabetes mellitus have been evaluated.


 :: Materials and Methods Top


Setting

The Kingdom of Bahrain is a group of small islands located at Arabian Gulf with an approximate population of 650,000. A primary health care organization with a network of 20 health centers across the country provides health care including dispensing essential drugs. Each of these health centers is equipped with laboratory facilities for routine investigations and a theater for minor surgical procedures. The number of primary care physicians in each health center varies between 4 and 11. Any patient requiring special investigations and consultation with specialists or admission is referred to Salmaniya Medical Centre (SMC) where secondary - tertiary care is provided.

Subjects and investigations

Diabetic hypertensive patients (initially identified based on the information gathered from laboratory investigation requests by primary care physicians and verified thereafter by medical records) were included. Laboratory investigation requests from primary care physicians for patients having chronic diseases such as hypertension and type 2 diabetes mellitus, those requiring routine blood chemistry assessment (fasting glucose, total cholesterol, creatinine, and potassium), and other optional investigations [low-density lipoprotein (LDL) cholesterol, triglycerides, uric acid and plasma renin activity, plasma aldosterone, and urinary catecholamines] [23] are routinely analyzed in SMC biochemistry laboratory.

The laboratory investigation requests for those with a diagnostic label of hypertension and type 2 diabetes were obtained between January 2001 and February 2001 from the biochemistry laboratory at SMC. Laboratory investigation reports were retrieved through the SMC database. These reports also included information about patients' age, gender and medical records number at the health centers. Medical records of eligible patients were subsequently retrieved manually at the health centers to confirm the diagnosis, to obtain BP records (during the first few follow-up visits after receipt of laboratory reports) and to obtain treatment modification or intervention (usually second or third visits over a period of 2-3 months thereafter), and to obtain information on drugs or other therapeutic interventions prescribed.

Operational definitions

A patient was labeled as diabetic hypertensive if he/she received antihypertensive and antidiabetics (oral antidiabetics and insulin) drugs concomitantly, and/or if the BP and hyperglycemia were controlled with nonpharmacologic interventions. Therapeutic target BP, fasting blood glucose (FBG), and glycated hemoglobin (HbA 1C ) were <130/<85 mm Hg, <6.1 mmol/l, and <7%, respectively. Overweight was defined as a body mass index (BMI) ≥25 - <30 kg/m 2 , and obesity as a BMI ≥ 30 kg/m 2 . Dyslipidemia was considered when the serum cholesterol concentration was >5.2 mmol/l, or the serum triglycerides concentration was >1.8 mmol/l or both, and if the patient was receiving lipid-lowering drugs. Subjects with a history of MI, angina pectoris, and coronary artery bypass surgery were pooled as a subgroup of ischemic heart diseases. Hyperuricemia was defined as serum uric acid >350 µmol/l for women and >440 µmol/l for men. Complementary (rational) antihypertensive combination therapy is defined as a combination of two or more antihypertensives with complementary mechanisms of action that are additive to provide optimal BP control. [10]

Drugs

Antihypertensive drugs available at health centers at the time of data collection were: angiotensin converting enzyme inhibitors (ACEIs) (captopril, lisinopril, enalapril, perindopril); b-blockers (atenolol, propranolol); calcium channel blockers (CCBs, immediate- and sustained-release nifedipine, immediate-release diltiazem and verapamil); diuretics (hydrochlorothiazide [HCTZ], HCTZ and triamterene fixed-dose combination, chlorthalidone, sustained-release indapamide); methyldopa, hydralazine and reserpine/dihydroergocristine/clopamide (fixed-dose) combination. Among antidiabetic drugs, biguanide (metformin), second-generation sulfonylureas (glibenclamide, gliclazide, glipizide), and various preparations of short (regular)- and intermediate-acting insulins were available.

Data analysis

Data were analyzed using Statistical Package for the Social Science (SPSS/PC+, Version 9.0). χ2 -test without Yate's correction was used to test the difference between proportions and two-tailed t -test for continuous variables. The 95% confidence intervals were calculated with Wald's method. A P -value < 0.05 was considered statistically significant.

Ethical approval

Permission to carry out the study was obtained from the Assistant Undersecretary for Primary Care, Ministry of Health, Bahrain. Confidentiality of both patient- and physician-related information was ensured.


 :: Results Top


Of 417 diabetic hypertensive patients 392 were included in this study, whereas, 25 (6%) were excluded because their medical records were nonretrievable. Among these 392 patients, 127 (32.4%) were men (mean age in years ± SD: 58.3 ± 10.5; median 61.0; range 29-79), whereas 265 (67.6%) were women (mean age 56.1 ± 10.9; median 56.0; range 35-89). The mean bodyweight (kg) was 81.0 ± 18.1 ( n = 78) for men, and 80.1 ± 18.5 ( n = 142) for women. The mean height (cm) for male and female patients was 168.3 ± 7.8 ( n = 78) and 155.0 ± 7.2 ( n = 142), respectively ( P < 0.001). Women had significantly greater mean BMI than men [33.3 ± 6.8 kg/m 2 ( n = 142) vs. 28.6 ± 5.3 kg/m 2 ( n = 78); P < 0.0001]. Women also had significantly greater waist circumference than men [108.4 ± 14.4 cm ( n = 90) vs. 101.6 ± 13.9 cm ( n = 45); P = 0.009]. No significant difference in mean waist-hip ratio for men and women was observed [0.99 ± 0.04 ( n = 44) vs. 0.99 ± 0.06 ( n = 90)].

Blood pressure and laboratory parameters of diabetic hypertensive men and women are presented in [Table 1]. The BP target <130/<85 mm Hg was achieved in 8.7% ( n = 11/127) men and 8.3% ( n = 22/265) women ( P = 0.99). The target HbA 1C concentration <7% was attained in 14.1% ( n = 11/78) of men and in 12.2% ( n = 18/147) of women ( P = 0.18). There were no gender differences in proportions of patients achieving the recommended BP and HbA 1C targets.

The most common antihypertensive drug class prescribed was ACEIs (54%); male patients were more often treated with ACEIs than female patients (63.7% vs. 49.4%; P = 0.006) [Table 2]. Approximately two-third of patients were on antihypertensive monotherapy (60.2%) (men 63% vs. women 58.9%, P = 0.43). No significant differences in prescribing pattern were observed between men and women with diabetic hypertension treated with either monotherapy or with antihypertensive combination therapies [Figure 1].

The overall proportion of noncomplementary two-drug antihypertensive combinations prescribed was 31.1% (men 41.1 vs. women 27.2; P = 0.13). ACEI/ β-blocker noncomplementary two-drug combination was 25.4%, prescribed to male patients in a rate significantly higher than in females ( P = 0.04; [Table 3]). Other noncomplementary two-drug regimens included combinations of methyldopa with either an ACEI (2.5%) or a diuretic (1.7%) or a β-blocker (0.8%), and a combination of losartan plus moduretic (a fixed dose HCTZ with amiloride) (0.8%). The overall proportion of noncomplementary three-drug antihypertensive combinations was 82.2% (men 72.8% vs. women 88.2%; P = 0.29). ACEI/β-blocker/diuretic-based regimen was the most common three-drug combination (42.9%) prescribed. The proportion of other noncomplementary three-drug regimens were as follows: ACEI/β-blocker/CCB (24.9%), ACEI/CCB/methyldopa (3.6%), ACEI/diuretic/methyldopa (3.6%), β-blocker/CCB/methyldopa (3.6%) and β-blocker/diuretic/ methyldopa (3.6%).

The overall prescription of oral antidiabetic agents and insulin according to gender is shown in [Table 2]. Glibenclamide was the most frequently prescribed drug in both genders (men 50.4% vs. women 52.1). Females were more often treated with insulin than male patients (12.5% vs. 6.3%; P = 0.04); no other significant differences with respect to drug selection [Table 2], and rank-order of prescribed antidiabetics, either as monotherapy or as combinations, were observed [Figure 1].

Approximately 13% of diabetic hypertensive patients were on lipid-lowering drugs; no gender difference was observed [Table 2]. The overall prescribing of antithrombotic aspirin was 11.5%; men were more often treated with aspirin than women (21.3% vs. 6.8%; P < 0.0001). The proportion of cardiovascular risk factors notably overweight, obesity, hypercholesterolemia, and hyperuricemia were significantly greater in women compared to men [Table 4]. Ischemic heart disease was more prevalent among male patients ( P = 0.02).


 :: Discussion Top


This prescription audit study revealed that in diabetic hypertensives a BP target ≤130/85 mm Hg was achieved only in 8.4% of patients treated at primary care setting in Bahrain. This rate of BP control was markedly lower than that reported in USA, [20] Saudi Arabia, [24] and in France [25] using BP < 130/80 mm Hg threshold; Sweden [19] using BP < 140/80 mm Hg; in Bangladesh and India [26] and more recently 19.7% in USA [27] using BP target < 130/85 mm Hg, a target comparable to that used in our study. We also found a lack of gender-based difference in the proportion of patients who achieved the recommended goal BP, a finding that corroborates [20] and differs [19] from other studies. Poor rate of BP control in our study may be partly due to: (a) prescribing of antihypertensive monotherapy to majority of patients [Figure 1], whereas combination of antihypertensives are often needed to achieve the recommended BP targets in diabetic hypertensive patients [8],[9],[10],[11],[12] ; approximately 10% of patients were on three or more drug combination therapy [Figure 1]; (b) prescribing noncomplementary two-drug combinations [8],[10],[12],[23] (31.2%) and three-drug combinations [12] (82.2%) [Table 3]; (c) most patients had metabolic syndrome, which increases the cardiovascular risk and renders the BP target difficult to achieve [28] ; (d) high prevalence of overweight - obesity in male (75.6%) and female (91.5%) patients [Table 4]; obesity is associated with elevated BP, diminished antihypertensive drug efficacy, and increased cardiovascular risk. [8],[23]

ACEIs were the most often prescribed antihypertensive drugs in our study, a profile comparable to findings of other studies. [1],[2],[20],[25],[27] ACEIs have favorable impact on cardiovascular and renal outcomes. [8],[9],[10],[11],[12] Men were more often prescribed ACEIs than women ( P < 0.05). The explanation for this prescribing pattern may be related to: (a) awareness of many primary care physicians about a lack of adverse effect of ACEIs on sexual function in men [29] ; and (b) higher incidence of ACEI-induced cough in women than in men. [30]

Comorbidity with diabetes and hypertension appears to be a risk factor, contributing independently to sexual dysfunction in men. [31] Sexual dysfunction has been often associated with the use of thiazide diuretics, b-blockers, and centrally acting adrenergic inhibitors. [29] Atenolol, the second ranked antihypertensive was prescribed in both genders (37.7% in male and 44.8% in female) at a daily dose of 100 mg. In addition to potential iatrogenic erectile dysfunction in male, [9],[12] β-blockers in high doses mask the symptoms of hypoglycemia, [9],[12],[31] and can result in adverse metabolic effects.

A reluctance of many physicians to prescribe diuretics was noted [Table 2], although low-dose diuretics are effective in patients with diabetic hypertension, and are associated with minimal dose-related sexual dysfunction [29] and adverse metabolic effects. [32] Low-dose diuretic, unless contraindicated, should be included as an essential component of combination therapy in hypertensives. [33] Low dose of thiazide in combination with potassium sparing diuretics, ACEIs, ARBs, β-blockers, and CCBs have been proven to be rational combinations. [8],[10],[12],[23] The use of diuretics in diabetic hypertensive patients has been reported to protect against coronary disease to an even greater degree than in nondiabetic hypertensives. [34] Appropriate low doses of diuretics and b-blockers, therefore, should be considered [29],[31] since 27.8% of male patients reported sexual problems in our study (data not shown).

Gender-based differences in antihypertensive drug use in general practice have been reported earlier. [35] Physician characteristics such as a lack of residency training in family medicine, and nonevidence-based attitude that men have greater absolute risk of coronary heart diseases than women, and higher prevalence of ankle edema among women were considered explanations for the choice of β-blockers in men and diuretics for hypertensive women. [36]

Further more, among older women with no history of cardiovascular diseases (CVD), other than hypertension, a drug regimen comprising CCB/diuretics was associated with greater risk of CVD mortality versus β-blocker/diuretics. Risks were similar for ACEI/diuretics and β-blockers/diuretics. [36] Monotherapy with diuretics was equal or superior to other monotherapies in preventing CVD complications of high BP in older women. [37]

As regards glycemic control, fewer than 13% (14.1% men; 12.2% women; P = 0.18) of patients (in whom HbA 1C data were available) achieved the target HbA 1C <7% in our study sample. This proportion was lower than that reported in USA. [20] Poor glycemic control in our study, at least in part, can be due to less intensive drug therapy. This view is supported by the finding that single drug therapy was prescribed for approximately 50% of male and female diabetic patients with hypertension [Figure 1]. In the United Kingdom Prospective Diabetics Study, only about 25% of patients treated with monotherapy achieved target HbA 1C <7% of whom 42% were on insulin. [38] At least 40% of patients with type 2 diabetes eventually required insulin to maintain adequate glycemic control. [39] Of 392 patients in our study, 41 (10.5%) were treated with insulin either alone or in combination with oral antidiabetics; 18 (4.6%) were on insulin alone, 20 (5.1%) were on two-drug combinations and 3 (0.8%) were on three-drug combinations (data not shown). The association between obesity in diabetic hypertensive females and poor glycemic control in our study partly explains why female patients received insulin at a rate significantly greater than males. A conservative use of insulin may be because: (a) some physicians erroneously view insulin to be the last resort therapy; and (b) a reluctance of others due to concerns about bodyweight gain and hypoglycemic risk. [40] Patient-related barriers to insulin therapy appear to play a minimal role since only 2.3% patients refused insulin therapy.

Metformin was relatively underutilized although the majority of patients in both genders were overweight or obese [Table 4]. Metformin is as effective as sulfonylurea in lowering HbA 1C concentration and results in moderate weight loss [41] ; diarrhea [42] may be the main reason for its underutilization. Newer oral antidiabetics with proven efficacy and safety should be included in the primary care essential drug list to expand the therapeutic options for maintaining target glycemic control.

Lipid-lowering drugs were underutilized although these drugs decrease the rate of coronary events in diabetic than nondiabetic subjects, [16] and need to be prescribed to all subjects with diabetes as if they had prior coronary heart disease. [1],[2],[17] A lack of gender-based difference was observed with regard to lipid-lowering drugs although: (a) mean total cholesterol was significantly greater in female patients [Table 1]; (b) LDL cholesterol for both genders was > 3.35 mmol/l (the cutoff level recommended for pharmacologic intervention); [43] and (c) the proportion of females with total cholesterol ≥5.2 mmol/l was significantly greater than in male. Although the lipid profile of our study population justifies intervention with statins, fibrates were used instead in about two-third of patients [Table 2], because statins were restricted for referral patients at the time of data collection.

Low-dose aspirin is considered as a primary prevention strategy in high-risk diabetic subjects [13] to reduce adverse clinical outcomes, especially major cardiovascular events. [6],[14] Contrary to the expectation, antithrombotic strategy has received little attention since aspirin was prescribed conservatively. Men were more likely to be on aspirin ( P < 0.0001; [Table 2]) because ischemic heart disease was more prevalent in men ( P = 0.02; [Table 4]).

Our study has confirmed that women with diabetes were less aggressively treated for many modifiable CVD risk factors than men with diabetes. Similar findings have been reported previously. [21],[22],[44],[45] An aggressive treatment of CVD risk factors in this population offers specific targets for improving diabetes care. The low rates of multiple risk factor control in patients with diabetes also highlight the challenges for attaining/achieving evidence-based goals in primary care. It would be interesting to determine the impact of more recent guidelines on BP and glycemic control rates and risk factor control. [3] In addition, differences in coping strategies in men and women with diabetes [46] also need to be further explored.

Limitation of study

Drug compliance, which is a major problem in patients with chronic diseases, has not been considered in this descriptive study. Gender as a determinant of BP and glycemic control from a developing country-perspective needs a further evaluation. The generalizability of our findings needs to be carefully considered within the framework of organization of the health care system of a country.


 :: Conclusion Top


In both men and women, BP and glycemia were inadequately controlled in diabetic hypertensive patients treated by primary care physicians. Prescribing of ACEIs and aspirin in favor of males, and insulin in favor of females, were the only observed gender-based differences in drug therapy. Cardiovascular preventive strategies have received little attention regardless of gender. Updating the primary care-essential drug list to provide more efficacious and complementary therapies for optimal BP and glycemic control is needed. Continuing professional education addressing pharmacotherapy should be encouraged. Effective prevention strategies to reduce CVD mortality and disability in developing countries are required. Gender-based treatment inequities also need to be addressed.

 
 :: References Top

1.Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al . International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombisis. JAMA 2006;295:180-9.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Steg PG, Bhatt DL, Wilson PW, D′Agostino R Sr, Ohman EM, Rother R, et al . One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206.  Back to cited text no. 2    
3.Graham I, Atar D, Borch-Johnson K, Boysen G, Burell G, Cifkova R, et al . European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (onsistent by representatives of nine societies and invited experts). Eur J Cardiovasc Prev Rehabil 2007;14:E1-40.   Back to cited text no. 3    
4.Diabetes in America. 2 nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 1995.  Back to cited text no. 4    
5.UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.   Back to cited text no. 5    
6.Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351:1755-62.  Back to cited text no. 6    
7.Fuller J, Stevens LK, Chaturvedi N, Holloway JF. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. Cochrane Database Syst Rev 2007;4:CD002188.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]
8.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al . The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560-72.  Back to cited text no. 8  [PUBMED]  
9.Working party of the International Federation (European Region). Hypertension in people with type 2 diabetes: Knowledge-based diabetes-specific guidelines. Diabetes Med 2003;20:972-87.  Back to cited text no. 9    
10.European Society of Hypertension-European Society of Cardiology Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.  Back to cited text no. 10    
11.Whitworth JA; World Health Organization, International Society of Hypertension Working Group. World Health Organization (WHO), International Society of Hypertension (ISH) Statement on management of hypertension. J Hypertens 2003;21:1983-92.  Back to cited text no. 11    
12.Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society Guidelines. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.  Back to cited text no. 12    
13.Clowell JA; American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2003;26:S87-8.  Back to cited text no. 13    
14.Antiplatelet Trial Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.  Back to cited text no. 14    
15.Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: Finding from the Scandinavian Simvastatin Survival Study. Diabetes Care 1999;22:1771-8.   Back to cited text no. 15  [PUBMED]  [FULLTEXT]
16.Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC-BHF Heart Protection Study of cholesterol lowering with simvastatin 5963 people with diabetes: A randomized placebo-controlled trial. Lancet 2003;361:2005-16.  Back to cited text no. 16  [PUBMED]  [FULLTEXT]
17.Juutilainen A, Lehto S, Rφnnemaa T, Pyφrδlδ K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": An 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901-7.  Back to cited text no. 17    
18.Oparil S, Miller AP. Gender and blood pressure. J Clin Hypertens (Greenwich) 2005;7:300-9.   Back to cited text no. 18  [PUBMED]  [FULLTEXT]
19.Nilsson PM, Theobald H, Journath G, Fritz T. Gender difference in risk factor control and treatment profile in diabetes: A study in 229 Swedish primary health care centres. Scand J Prim Health Care 2004;22:27-31.  Back to cited text no. 19  [PUBMED]  
20.McFarlane SI, Castro J, Kaur J, Shin JJ, Kelling D Jr, Farag A, et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: Outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) 2005;7:73-80.  Back to cited text no. 20    
21.Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Steven M, et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 2008;31:69-74.  Back to cited text no. 21    
22.Gouni-Berthold I, Berthold HK, Mantzaros CS, Bohn M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care 2008;31:1389-91.  Back to cited text no. 22    
23.World Health Organization - International Society of Hypertension. Guidelines for the management of mild hypertension. J Hypertens 1999;171:151-81.  Back to cited text no. 23    
24.Alsuwaida A. Effect of salt intake on blood pressure in diabetic hypertensive patients in Saudi Arabia. Saudi Med J 2007;28:909-12.  Back to cited text no. 24  [PUBMED]  
25.Charpentier G, Genes N, Vaur L, Amar J, Clerson P, Cambou JP, et al . Control of diabetes and cardio-vascular risk factors in patients with type 2 diabetes: A nationwide French survey. Diabetes Metab 2003;29:152-8.   Back to cited text no. 25    
26.Hypertension Study Group. Prevalence, awareness, treatment and control of hypertension among the elderly in Bangladesh and India: A multicentric study. Bull World Health Organ 2001;79:490-500.  Back to cited text no. 26  [PUBMED]  
27.Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patient with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care 2005;11:206-10.  Back to cited text no. 27  [PUBMED]  [FULLTEXT]
28.Kaplan NM. The deadly quartet: Upper body adiposity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989;149:1514-20.  Back to cited text no. 28  [PUBMED]  
29.Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 1999;18:5-24.  Back to cited text no. 29  [PUBMED]  
30.Visser LE, Stricker BH, van der Velden J, Paes AH, Bakker A. Angiotensin-converting enzyme inhibitors associated cough: A population-based case control study. J Clin Epidemiol 1995;48:851-7.  Back to cited text no. 30  [PUBMED]  [FULLTEXT]
31.High Blood Pressure Education Program Working Group. Report on hypertension in diabetes. Hypertension 1994;23:145-58.  Back to cited text no. 31    
32.Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al . Influence of long-term, low-dose, diuretic-based antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998;158:741-51.  Back to cited text no. 32  [PUBMED]  [FULLTEXT]
33.ALLHAT Offices and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000;288:2981-97.  Back to cited text no. 33    
34.Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al . Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.  Back to cited text no. 34  [PUBMED]  
35.Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A. Sex difference in antihypertensive drug use: Determinants of choice of medication for hypertension. J Hypertens 1998;16:1545-53.  Back to cited text no. 35  [PUBMED]  [FULLTEXT]
36.Klungel OH, Paes AH, de Boer A, Kuyvenhoven MM, Seidell JC, Bakker A. Sex difference in medication choice for hypertension in general practice: A study with written case simulations. Pharm World Sci 2000;22:140-6.  Back to cited text no. 36    
37.Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, Kotchen T, Mouton C, et al . Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004;292:2849-59.   Back to cited text no. 37  [PUBMED]  [FULLTEXT]
38.American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study (UKPDS). Diabetes Care 2003;36:S28-32.  Back to cited text no. 38    
39.Centers for Disease Control and Prevention. Available from: http://www. cdc.gov/diabetes/ faqs.htm. [last accessed 2006 Aug 30].  Back to cited text no. 39    
40.Uncontrolled diabetes. Science Writer′s Guide to Uncontrolled Diabetes. Addressing the new diabetes epidemic: Uncontrolled diabetes. Available from: http://www.nyas.org/ebrief/diabetes/resources.pdf. [last accessed on 2006 Apr 29].   Back to cited text no. 40    
41.Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrionol Metab Clin North Am 2001;30:909-33.  Back to cited text no. 41    
42.Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol 1999;94:2165-70.   Back to cited text no. 42  [PUBMED]  
43.American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statements). Diabetes Care 2003;26:S83-6.  Back to cited text no. 43  [PUBMED]  [FULLTEXT]
44.Basile JN, Lackland DT, Basile JM, Riehle JE, Egan BM. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and non-diabetic patients with hypertension. J Clin Hypertens (Greenwich) 2004;6:18-25.   Back to cited text no. 44    
45.Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28:514-20.  Back to cited text no. 45  [PUBMED]  [FULLTEXT]
46.Gεfvels C, Wδndell PE. Coping strategies in men and women with type 2 diabetes in Swedish primary care. Diabetes Res Clin Pract 2006;71:280-9.  Back to cited text no. 46    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]

This article has been cited by
1 Need for and Access to Health Care and Medicines: Are There Gender Inequities?
Wagner, A.K. and Graves, A.J. and Fan, Z. and Walker, S. and Zhang, F. and Ross-Degnan, D.
PLoS ONE. 2013; 8(3)
[Pubmed]
2 Does access to medicines differ by gender? Evidence from 15 low and middle income countries
Stephens, P. and Ross-Degnan, D. and Wagner, A.K.
Health Policy. 2013; 110(1): 60-66
[Pubmed]
3 Sex-dimorphism in Cardiac Nutrigenomics: effect of Trans fat and/or Monosodium Glutamate consumption
Kate S Collison, Marya Z Zaidi, Zakia Maqbool, Soad M Saleh, Angela Inglis, Nadine J Makhoul, Razan Bakheet, Mohammed Shoukri, Futwan A Al-Mohanna
BMC Genomics. 2011; 12(1): 555
[VIEW] | [DOI]
4 Hypertension in a primary care setting: Control and pattern of prescribing
Nasser, J.
Bahrain Medical Bulletin. 2010; 32(3): 1-9
[Pubmed]
5 Gender disparity in the management and outcomes of cardiovascular risk factors in diabetic and hypertensive patients: A cross-cultural phenomenon
Morton-Rias, D. and McFarlane, S.
Journal of Postgraduate Medicine. 2008; 54(4): 250-251
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article
Online since 12th February '04
© 2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow